Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, $0.0001 par value
-
Shares outstanding
-
53,512,954,839
-
Total 13F shares
-
1,170,067
-
Share change
-
+619,327
-
Total reported value
-
$1,181,319
-
Price per share
-
$1.01
-
Number of holders
-
16
-
Value change
-
+$593,371
-
Number of buys
-
5
-
Number of sells
-
5
Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) as of Q3 2025
As of 30 Sep 2025,
Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,170,067 shares.
The largest 10 holders included
Cresset Asset Management, LLC, Palo Alto Investors LP, HighTower Advisors, LLC, Omnia Family Wealth, LLC, Cerity Partners LLC, Virtu Financial LLC, TWO SIGMA SECURITIES, LLC, Independent Advisor Alliance, Accent Capital Management, LLC, and NewEdge Advisors, LLC.
This page lists
16
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.